Eligibility criteria
Condition
Pulmonary Fibrosis
Sex
Females and Males
Age
40-80 years
Inclusion criteria
Show details
- Diagnosis of IPF based on American Thoracic Society (ATS) guidelines
Exclusion criteria
Show details
- Subjects with end-stage
- Previous treatment with etanercept or other TNF antagonists (eg, a TNF monoclonal
antibody or a soluble TNF-receptor)
- Receipt of any investigational drug or biological agent within 4 weeks of screening
visit